Fundamental Data for XNPT

XENOPORT I(NSDQ:XNPT)

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body''s natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.

# Employees: 181

Address: 3410 Central Expressway,Santa Clara,CA,USA

Phone: 408-616-7200

Fax: 408-616-7210

Website: www.xenoport.com

Email: IR@XenoPort.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

William J. Rieflin (Presi.)

William G. Harris (Sr. V.P. Fin.; C.F.O.)

David R. Savello Ph.D. (Sr. V.P. Develop.)

Mark A. Gallop Ph.D. (Sr. V.P. Res.)

Ronald W. Barrett Ph.D. (C.E.O.; Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/11/2010

Mean EPS (Next Qtr): ($0.77)

Mean EPS (Year): ($2.45)

Mean Estimate(Long Term): $33.00

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 15

Shares Performance

Period	XNPT	Compare to S&P
YTD	-34.81 %	-46.05 %
4 Weeks	-12.52 %	-13.46 %
12 Weeks	-8.04 %	-13.31 %

Shares Information

Analyst Coverage: Y

Avg Volume: 514264

Shares Outstanding: 30M

Market Cap: $0.49B

52 Week High: $33.65

52 Week Low: $13.58

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 XNPT split by factor of 1.500

Earnings Performance

EPS Growth in Last Quarter: -6.58 %

EPS Growth in Last Year: 15.62 %

Sales Growth in Last Quarter: -77.99 %

Sales Growth in Last Quarter: -91.71 %

Financials

Qtr Book Value: $3.53

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 12.650